EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, MyelomaOctober 19, 2021
Research Grant Application – Shared-Decision Making in MyelomaMPE, Myeloma, Patient evidenceOctober 11, 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosisJune 23, 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidenceJune 21, 2021
EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, MyelomaJune 14, 2021
